Global Chondrosarcoma Pipeline Insight Report 2021: Comprehensive Insights About 6+ Companies and 6+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chondrosarcoma – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Chondrosarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chondrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.

Chondrosarcoma Emerging Drugs Chapters

This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chondrosarcoma Emerging Drugs

INBRX-109: Inhibrx

INBRX-109 is a humanized recombinant tetravalent single domain IgG1 antibody targeting the human death receptor 5. INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate currently being evaluated in patients diagnosed with chondrosarcoma, mesothelioma, pancreatic adenocarcinoma, gastric adenocarcinoma, and synovial sarcoma. INBRX-109 agonizes DR5 to induce tumor selective programmed cell death.

Ifosfamide: Atlanthera

Ifosfamide is a DNA cross-linking agent and an inhibitor of DNA synthesis. It is being developed by Atlanthera for the treatment of osteosarcoma, chondrosarcoma, and ewing’s sarcoma. The drug is currently in preclinical studies.

Chondrosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chondrosarcoma

There are approx. 6+ key companies which are developing the therapies for Chondrosarcoma. The companies which have their Chondrosarcoma drug candidates in the most advanced stage, i.e. Phase I include, Inhibrx.

Phase

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chondrosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chondrosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.

Chondrosarcoma Report Insights

• Chondrosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chondrosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chondrosarcoma drugs?
• How many Chondrosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chondrosarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chondrosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Roche
• ImmunityBio
• Inhibrx
• AnHeart Therapeutics
• Atlanthera

Key Products

• Vismodegib
• Aldox
• INBRX-109
• AB 218
• Ifosfamide

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5ify6e

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900